导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.91% | 948/4773 |
| 近一周 | -2.71% | 2909/5462 |
| 近一月 | -8.47% | 4258/5421 |
| 近一季 | -1.27% | 963/5209 |
| 近半年 | 5.15% | 788/4920 |
| 近一年 | 6.91% | 1391/4366 |
| 近两年 | 92.75% | 661/2954 |
| 近三年 | 59.86% | 446/2253 |
| 成立以来 | 39.28% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.36% 3817/4961 |
22.58% 1120/5312 |
- - |
- - |
| 2025 | 34.15% 1076/4813 |
4.18% 982/3635 |
0.40% 2667/4076 |
38.90% 838/4524 |
-7.67% 3825/4813 |
| 2024 | 13.90% 1099/3463 |
-3.73% 1552/2808 |
-4.98% 1607/3014 |
17.26% 1220/3129 |
6.18% 537/3463 |
| 2023 | 2.29% 324/2656 |
23.27% 115/2280 |
-3.98% 992/2385 |
-11.22% 2048/2515 |
-2.66% 507/2655 |
| 2022 | -30.26% 1627/2207 |
-21.44% 1627/1919 |
1.39% 1482/2016 |
-16.17% 1411/2113 |
4.44% 544/2208 |
| 2021 | 9.42% 456/1822 |
-6.33% 995/1255 |
11.74% 361/1330 |
-3.27% 625/1466 |
8.07% 164/1822 |
| 2020 | - - |
- - |
24.17% 177/1067 |
2.04% 1012/1164 |
5.81% 772/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证科技50策略ETF联接A VS. 长安沪深300非周期A(740101) |